We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Cenix, Applied Biosystems and Dresden University Announce Collaboration


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cenix, Applied Biosystems and Dresden University Announce Collaboration "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Cenix BioScience GmbH, Applied Biosystems, an Applera Corporation business, and the Biotechnology Centre (Biotec) of the Technische Universit Dresden (TUD) have announced a collaboration to establish a joint facility to pioneer the convergence of two of research methodologies: functional genomics and proteomics.

The facility will enable scientists from the three organizations to develop and deliver research tools and methodologies that enable detailed and probative analyses of the cellular functions of therapeutically-relevant genes.

As such, this work promises to improve the predictive value of early pre-clinical drug development, ultimately reducing the risks of unwanted side effects from future medicines.

A German federal grant of 1.2 Million Euros has been issued to support the efforts of this two-year project through the BioChance Plus grant program.

The two-year project will stretch the limits of today's advanced technologies for analyzing gene function and drug action through cellular phenotyping, i.e. the detection and measurement of changes in the behavior of living cells after the application of pharmaceutical agents or other treatments that modulate gene expression.

Until now, the broadest, highest content phenotyping approaches could only probe the so-called transcriptome level of gene expression, whereby cDNA microarrays have enabled measurements of thousands of gene transcripts simultaneously.

However, in order to truly understand the full complexity of gene function, phenotypes must be examined at the level of the final, functional gene product: the protein.

Despite the success of high content microscopy-based assays, broad proteome-level profiling has remained much less developed, primarily due to inherent limitations of antibody-based approaches.

The present project will seek to overcome these limitations by developing broad, quantitative surveys of protein levels in RNAi- and drug-treated cells using antibody-independent, mass spectrometry-based analyses.

This initiative represents an effort by Cenix in its continuing mission to strengthen and broaden the discovery potential of RNAi-based experimentation through high-resolution phenotypic analyses.

Cenix will integrate the newly developed capabilities within its range of RNAi-based research service programs for target discovery, target validation and drug mode of action analyses.

"This is the natural next step in high content analysis not only for RNAi experiments, but also for studying therapeutic drug effects and a wide variety of other experimental strategies common to both basic and applied research," notes Christophe Echeverri, Ph.D., CEO/CSO of Cenix.

Technologies for the collaboration from Applied Biosystems will include mass spectrometry systems, iTRAQ protein labeling reagents, customized TaqMan gene expression assays, and its Ambion range of RNAi knock-down reagents.

Applied Biosystems' contributions to the project will be coordinated from its Science Centre Europe, located in Darmstadt, Germany.

"Applied Biosystems has a 25-year history of collaborating with leading researchers in academia and industry on a global basis," said Lars Holmkvist, Applied Biosystems president for Europe.

"We are confident that this collaboration in Europe will enable significant innovative advances in cell biology and for marker discovery and validation in the pharmaceutical industry."

This collaboration is a further manifestation of the industry-academic cooperation being fostered within Dresden life science research community.

The facility will be located within the Dresden Bio-Innovation Centre, adding further strength to the existing Biotec research group for Proteomics now led by Prof. Bernard Hoflack.

"We are proud to demonstrate again the pivotal role of the Biotec for connecting scientific, social and economic interests in the Dresden life science research community," said Professor Hoflack.

"As a researcher focused on bone biology and osteoporosis, I welcome this cooperation with industrial partners to help accelerate and enhance our basic research efforts, facilitating their translation towards future therapeutic applications."

Advertisement